Kite Pharma

Kite Pharma is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to harness the power of a patient's immune system to eradicate cancer cells. This is done using engineered autologous cell therapy (eACT). The engineered T cells are designed to recognize and destroy cancer cells. Kite anticipates potential launch and commercialization of its first lead product (KTE-C19) in 2017.
Company Growth (employees)
Type
Public
HQ
Santa Monica, US
Founded
2009
Size (employees)
447 (est)
Kite Pharma was founded in 2009 and is headquartered in Santa Monica, US

Kite Pharma Office Locations

Kite Pharma has offices in Santa Monica, El Segundo, Seattle, New York and in 31 other locations
Santa Monica, US
Phoenix, US
Miami, US
Dallas, US
Minneapolis, US
Buffalo, US
Tampa, US
Baltimore, US
Charlotte, US
Kansas City, US
Denver, US
St. Louis, US
Indianapolis, US
Cleveland, US
Nashville, US
Los Angeles, US
Philadelphia, US
Richmond, US
Amsterdam, NL
London, GB

Kite Pharma Metrics

Kite Pharma Summary

Market capitalization

$4.2 b

Closing share price

$84.9
Kite Pharma's current market capitalization is $4.2 b.

Kite Pharma Financials

Kite Pharma's revenue is $22.2 m in FY, 2016
FY, 2016

Revenue

$22.2 m

Net Income

($267.1 m)

Kite Pharma Market Value History

Kite Pharma Job Categories

Kite Pharma Online Presence

Kite Pharma News

Kite Pharma Company Life

You may also be interested in